Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection

Substance Use and Misuse

Volumn 45, Issue 4, 2010, Pages 496-514

  Canfield, Kelly M ^a   Smyth, Emily ^a   Batki, Steven L ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attitudes; Beliefs; Experiences; Hepatitis C; Knowledge; Methadone; Opioid; Psychiatry; Substance use; Treatment

Indexed keywords

METHADONE;

ADDICTION; ADULT; ARTICLE; ATTITUDE TO HEALTH; FEMALE; HEPATITIS C; HUMAN; MALE; PATIENT ATTITUDE; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT;

ADULT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; MALE; METHADONE; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION AS TOPIC; SUBSTANCE-RELATED DISORDERS;

EID: 76849108801     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826080903452538     Document Type: Article

References (59)

1. Amon, J. J., Garfein, R. S., Ahdieh-Grant, L., Armstrong, G., Ouellet, L. J., Latka, M. H., et al. (2008). Prevalence of hepatitis C virus infection among injection drug users in the United States, 1999-2004. Clinical Infectious Diseases, 46:1852-1858.
2. Astone, J. A., Strauss, S. M., Munoz-Plaza, C., Hagan, H., Des Jarlais, D. C. (2005). Providing support to drug users infected with hepatitis C: the role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions, 3(1):33-45.
3. Backmund, M., Meyer, K., Von Zielonka, M., Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34(1):188-193.
4. Batki, S. L., Cornell, M. E., Peek, R. M. H. (2002, June). Hepatitis C in an upstate New York methadone maintenance treatment program: preliminary analysis. (oral presentation). Annual Meeting of the College on the Problems of Drug Dependence, Quebec City .
5. Best, D., Noble, A., Finch, E., Gossop, M., Sidwell, C., Stang, J. (1999). Accuracy of perceptions of hepatitis B and C status: cross-sectional investigation of opiate addicts in treatment. BMJ, 319:290-291.
6. Biener, L., Abrams, D. B. (1991). The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychology, 10(5):360-365.
7. Bonkovsky, H. L., Tice, A. D., Yapp, R. G., Bodenheimer, H. C., Monto, A., Rossi, S. J., et al. (2008). Efficacy and safety of peginterferon alpha-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology, 103:2757-2765.
8. Carey, J., Perlman, D. C., Friedmann, P., Kaplan, W. M., Nugent, A., Deutscher, M., et al. (2005). Knowledge of hepatitis among drug injectors at a syringe exchange program. Journal of Substance Abuse Treatment, 29:47-53.
9. Cawthorne, C. H., Rudat, K. R., Burton, M. S., Brown, K. E., Luxon, B. A., Janney, C. G., et al. (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 91(1):149-159.
10. Crofts, N., Jolley, D., Kaldor, J., van Beek, I., Wodak, A. (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology Community Health, 51(6):692-697. (Pubitemid 28014247)
11. Dalgard, K., Bjoro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., et al. (2002). Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. European Addiction Research, 8:45-49.
12. Diaz, T., Des Jarlais, D. C., Vlahov, D., Perlis, T. E., Edwards, V., Friedman, S. R., et al. (2001). Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upperManhattan, New York City. American Journal of Public Health, 91(1):23-30.
13. Doab, A., Treloar, C., Dore, G. L. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Disease, 40(S5):S313-S187.
14. Dore, G. J., Law, M., MacDonald, M., Kaldor, J. M. (2003). Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 26:171-184.
15. Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., et al. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? New England Journal of Medicine, 345(3):211-215.
16. Fabris, P., Tositti, G., Giordani, M. T., Baldo, V., Grasso, A., Pignattari, E., et al. (2006). Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle. Alimentary Pharmacology and Therapeutic, 23(8):1161-1170.
17. Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136(4):288-292.
18. Ferrando, S. J., Batki, S. L. (2000). Substance abuse and HIV infection. New Directions for Mental Health Service, 87:57-67.
19. Garfein, R. S., Doherty, M. C., Monterroso, E. R., Thomas, D. L., Nelson, K. E., Vlahov, D. (1998). Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 18(Suppl. 1):S11-S19.
20. Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T. Showler, G., et al. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93:141-147.
21. Gupta, K., Romney, D., Briggs, M., Benker, K. (2007). Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals. Journal of Community Health, 32(4):221-230.
22. Hagan, H., Des Jarlais, D. C., Stern, R., Lelutiu-Weinberger, C., Scheinmann, R., Stauss, S., et al. (2007). HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy, 18:341-351.
23. Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Duchin, J. S., Alexander, E. R. (2001). Sharing of drug preparation equipment a risk factor for hepatitis C. American Journal of Public Health, 91:42-46.
24. Hahn, J. A., Page-Shafer, K., Lum, P. J., Bourgois, P., Stein, E., Evans, J. L., et al. (2002). Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases, 186:1558-1564.
25. Hallinan, R., Byrne, A., Amin, J., Dore, G. J. (2005). Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of Gastroenterology and Hepatology, 20(7):1082-1086.
26. Heimer, R., Clair, S., Grau, L. E., Bluthenthal, R. N., Marshall, P. A., Singer, M. (2002). Hepatitisassociated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97:1277-1287.
27. Jowett, S. L., Agarwal, K., Smith, B. C., Craig, W., Hewett, M., Bassendine, D., et al. (2001). Managing chronic hepatitis C acquired through intravenous drug use. QJM, 94:153-158.
28. Krantz, M. J., Mehler, P. S. (2004). Treating opioid dependence: growing implications for primary care. Archives of Internal Medicine, 164(3):77-88.
29. Kwiatkowski, C. F., Booth, R. E. (2001). Methadone maintenance as HIV risk reduction with streetrecruited injection drug users. Journal of Acquired Immune Deficiency Syndromes, 26;483-489.
30. Lavanchy, D. (2009). The global burden of hepatitis. Liver International: Official Journal of the International Association for the Study of the Liver, 29(Suppl. 1):S74-S81.
31. Litwin, A. H., Soloway, I., Gourevitch, M. N. (2005). Integrating services for injection drug users infected with hepatitis C with methadone maintenance treatment: challenges and opportunities. Clinical Infectious Diseases, 40:S339-S345.
32. Mauss, S., Berger, F., Goelz, J., Jacob, B., Schutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40:120-124.
33. McCarthy, J. J., Flynn, N. (2001). Hepatitis C in methadone maintenance patients: prevalence and public policy implications. Journal of Addictive Diseases, 20(1):19-31.
34. Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., et al. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33:126-133.
35. Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C.P., Druley, P., Navaline, H., et al. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6(9):1049-1056.
36. Morrill, J. A., Shrestha, M.,Grant, R. (2005). Barriers to the treatment of hepatitis C: patient, provider, and system factors. Journal of General Internal Medicine, 20:754-758.
37. Moss, A. R., Vranizan, K., Gorter, R., Bacchetti, P., Watters, J., Osmaond, D. (1994). HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS, 8:223-231.
38. Munoz-Plaza, C. E., Strauss, S., Astone-Tweerell, J., Des Jarlais, D., Gwadz, M., Hagan, H., et al. (2008). Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. International Journal of Drug Policy, 19:71-78.
39. Murrill, C. S., Weeks, H., Castrucci, B. C., Weinstock, H. S., Bell, B. P., Spruill, C., et al. (2002). Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health, 92(3):385-387.
40. National Institutes of Health (NIH). (2002). National Institutes of Health consensus development conference statement: management of hepatitis C, June 10-12. Hepatology, 36(Suppl.):S3-S20.
41. Novick, D. M., Kreek, M. J. (2008). Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction, 103(6):905-918.
42. Perez, J. F., Farrington, L. A., Pecorano, C., Hutin, Y. J. F., Armstrong, G. L. (2004). Estimated global prevalence of hepatitis C virus infection. Paper presented at 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA; Sept. 30-Oct. 3, 2004.
43. Reynolds, G. L., Fisher, D. G., Jaffe, A., Edwards, J. (2006). Follow-up for medical care among drug users with hepatitis C. Evaluations & the Health Profession, 29(4):355-367.
44. Rounsaville, B. J., Kosten, T. R. (2000). Treatment for opioid dependence: quality and access. JAMA, 283(10):337-339.
45. Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldgerg, D.,Wiessing, L. (2002).Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiology and Infection, 129(3):557-585.
46. Shepard, C. W., Finelli, L., Alter, M. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases, 5:558-567.
47. Sorensen, J. L., Copeland, A. L. (2000). Drug abuse treatment as an HIV prevention strategy: a review. Drug and Alcohol Dependence, 59:17-31.
48. Stein, M. D.,Maksad, J.,Clarke, J. (2001). HepatitisCdisease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence, 61:211-215.
49. Strader, D. B., Wright, T., Thomas, D. L., Seeff, L. B., American Association for the Study of Liver Diseases. (2004). Diagnosis, management, and treatment of Hepatitis C. Hepatology, 39(4):1147-1171.
50. Strauss, S. M., Astone-Twerell, J., Munoz-Plaza, C. E., Des Jarlais, D. C., Gwadz, M., Hagan, H., et al. (2007). Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research, 7:39.
51. Stroove,M. A., Gifford, S. M., Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 77:81-86.
52. Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence, 67:117-123.
53. Sylvestre, D. L. (2005). Approaching treatment for hepatitis C virus infection in substance users. Clinical Infectious Diseases, 41:S79-S82.
54. Thiede, H., Hagan, H., Murrill, C. S. (2000). Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 77:331-345.
55. Thorpe, L., Ouellet, L., Hershow, R., Bailey, S.,Williams, I.,Monterosso, E. (2000). The mulitperson use of non-syringe injection equipment and risk of hepatitis C infection in a cohort of young adult injection drug users, Chicago 1997-1999. Annals of Epidemiology, 10:472-473.
56. Thorpe, L. E., Ouellet, L. J., Hershow, R., Bailey, S. L., Williams, I. T., Williamson, J., et al. (2002). Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155:645-653.
57. Van Thiel, D. H., Anantharaju, A., Creech, S. (2003). Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology, 98(10):2281-2288.
58. Walley, A. Y., White, M. C., Kushel, M. B., Song, Y. S., Tulsky, J. P. (2005). Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 28:181-187.
59. Willner-Reid, J., Belendiuk, K. A., Epstein, D. H., Schmittner, J., Preston, K. L. (2008). Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users onmethadone maintenance. Journal of Substance Abuse Treatment, 35:78-86.